Latest Period
Q2 2026
Security Snapshot
CORCEPT THERAPEUTICS INC - Common Stock, $0.001 par value (CORT) Institutional Ownership
CUSIP: 218352102
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
418
Shares (Excl. Options)
82,164,971
Price
$86.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value
- Symbol
- CORT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 82,164,971
- Total 13F value
- $7,146,082,272
- Portfolio coverage rank
- 0.01%
- Share change
- +2,969,974
- Value change
- +$350,443,684
- Number of holders
- 418
- Shares outstanding
- 107,380,163
- SEC-reported price per share
- $118.32
- Insider filing price
- $118.32
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CORT - CORCEPT THERAPEUTICS INC - Common Stock, $0.001 par value is tracked under CUSIP 218352102.
- 418 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 349 to 418 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $3,202,011,138 to $7,146,082,272.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 418 institutions filings for Q2 2026.
Security key
218352102
Latest holder period
Q2 2026
13F holders
418
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
CORT full holder history
CORCEPT THERAPEUTICS INC SEC filings
CORCEPT THERAPEUTICS INC company facts
CORCEPT THERAPEUTICS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 218352102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
CORT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | -14% | $846,969,867 | -$132,857,230 | 11,539,099 | -14% | BlackRock, Inc. | 30 Jun 2025 |
| INGALLS & SNYDER LLC | 6.8% | -12% | $292,790,314 | -$36,692,379 | 7,263,466 | -11% | INGALLS & SNYDER LLC | 31 Dec 2025 |
| BELANOFF JOSEPH K | 6.3% | $499,599,592 | 6,822,335 | Joseph K. Belanoff | 31 Dec 2024 | |||
| RENAISSANCE TECHNOLOGIES LLC | 4.9% | -11% | $482,017,741 | -$45,521,009 | 5,261,628 | -8.6% | Renaissance Technologies LLC | 01 Apr 2026 |
As of 30 Jun 2026, 418 institutional investors reported holding 82,164,971 shares of CORCEPT THERAPEUTICS INC - Common Stock, $0.001 par value (CORT). This represents 77% of the company’s total 107,380,163 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
61%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12% | 12,432,023 | +2.3% | 0.02% | $1,080,964,444 |
| INGALLS & SNYDER LLC | 7.4% | 7,934,507 | +4.3% | 19% | $689,905,000 |
| RENAISSANCE TECHNOLOGIES LLC | 4.9% | 5,261,628 | -7.4% | 0.63% | $457,498,555 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7% | 5,044,638 | +4.6% | 0.02% | $438,631,274 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 4,172,482 | +2.3% | 0.01% | $362,797,310 |
| Parallel Advisors, LLC | 3.7% | 3,962,177 | -0.38% | 5.3% | $344,511,290 |
| FMR LLC | 3.1% | 3,337,618 | +4.6% | 0.01% | $290,205,885 |
| STATE STREET CORP | 3.1% | 3,279,381 | +2.5% | 0.01% | $285,150,433 |
| AQR CAPITAL MANAGEMENT LLC | 2.4% | 2,582,561 | +536% | 0.08% | $224,553,662 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,532,198 | -6.7% | 0.01% | $220,214,154 |
| FIRST TRUST ADVISORS LP | 1.7% | 1,829,545 | -16% | 0.09% | $159,078,937 |
| TANG CAPITAL MANAGEMENT LLC | 1.4% | 1,500,000 | 0% | 5.9% | $130,425,000 |
| UBS Group AG | 1.3% | 1,377,658 | +1% | 0.02% | $119,787,363 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 1,318,821 | -15% | 0.02% | $114,676,371 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.1% | 1,157,580 | +3.4% | 0.01% | $100,651,581 |
| MORGAN STANLEY | 1.1% | 1,137,558 | +12% | 0.01% | $98,910,840 |
| D. E. Shaw & Co., Inc. | 0.82% | 883,001 | -25% | 0.05% | $76,776,937 |
| Cerity Partners LLC | 0.74% | 797,119 | +8.9% | 0.08% | $69,309,496 |
| MPM BIOIMPACT LLC | 0.72% | 771,028 | -22% | 4.1% | $67,040,885 |
| NORTHERN TRUST CORP | 0.7% | 753,796 | +17% | 0.01% | $65,542,562 |
| EMERALD ADVISERS, LLC | 0.7% | 748,325 | +264% | 1.5% | $65,066,859 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 0.66% | 710,106 | 0.17% | $61,743,697 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.65% | 695,532 | 0.22% | $60,476,507 | |
| VANGUARD FIDUCIARY TRUST CO | 0.57% | 614,078 | +4% | 0.01% | $53,394,082 |
| TWO SIGMA INVESTMENTS, LP | 0.57% | 610,078 | -36% | 0.04% | $53,046,282 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 82,164,971 | $7,146,082,272 | +$350,443,684 | $86.95 | 418 |
| 2026 Q1 | 79,454,442 | $3,202,011,138 | +$152,550,904 | $40.31 | 349 |
| 2025 Q4 | 76,610,607 | $2,668,599,587 | -$117,770,292 | $34.80 | 384 |
| 2025 Q3 | 77,152,974 | $6,407,786,320 | -$135,227,246 | $83.11 | 424 |
| 2025 Q2 | 78,953,366 | $5,792,808,674 | -$256,092,991 | $73.40 | 418 |
| 2025 Q1 | 81,954,269 | $9,118,688,561 | -$126,808,558 | $114.22 | 408 |
| 2024 Q4 | 84,197,994 | $4,242,065,667 | -$207,314,469 | $50.39 | 362 |
| 2024 Q3 | 88,403,089 | $4,090,692,212 | +$3,394,284 | $46.28 | 316 |
| 2024 Q2 | 89,225,655 | $2,899,048,485 | -$128,567,810 | $32.49 | 282 |
| 2024 Q1 | 93,600,393 | $2,357,405,516 | +$206,853,940 | $25.19 | 283 |
| 2023 Q4 | 84,732,406 | $2,752,093,285 | +$61,774,959 | $32.48 | 269 |
| 2023 Q3 | 83,019,792 | $2,261,938,980 | +$53,168,814 | $27.24 | 244 |
| 2023 Q2 | 81,489,147 | $1,813,024,077 | -$128,901,748 | $22.25 | 224 |
| 2023 Q1 | 87,299,563 | $1,890,881,420 | +$97,037,592 | $21.66 | 231 |
| 2022 Q4 | 83,493,481 | $1,696,055,001 | -$86,283,839 | $20.31 | 241 |
| 2022 Q3 | 87,114,680 | $2,234,275,240 | +$46,310,026 | $25.64 | 225 |
| 2022 Q2 | 85,057,351 | $2,023,773,420 | +$98,901,040 | $23.78 | 214 |
| 2022 Q1 | 81,373,846 | $1,836,938,219 | +$19,570,522 | $22.52 | 214 |
| 2021 Q4 | 80,562,329 | $1,594,701,243 | -$8,205,377 | $19.80 | 199 |
| 2021 Q3 | 80,869,592 | $1,591,453,895 | +$4,936,347 | $19.68 | 193 |
| 2021 Q2 | 80,507,190 | $1,769,402,198 | -$27,080,717 | $22.00 | 193 |
| 2021 Q1 | 81,631,723 | $1,941,273,564 | -$37,899,526 | $23.79 | 205 |
| 2020 Q4 | 83,389,910 | $2,180,799,586 | -$129,685,932 | $26.16 | 219 |
| 2020 Q3 | 89,228,523 | $1,552,636,140 | +$5,152,396 | $17.40 | 215 |
| 2020 Q2 | 89,585,381 | $1,506,658,948 | +$28,288,519 | $16.82 | 215 |